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and thus one can ‘fine-tune’ the
pharmacological activity of the endo-
genous ligand. Such compounds could
offer not only enhanced CB1R selec-
tivity, but also reduced receptor down-
regulation and inter-receptor
promiscuity (Kulkarni et al, 2016).
One such compound GAT211 in-
creases CB1R effects, demonstrates
good efficacy in rodent models of
chronic pain without demonstrating
acute tolerance, rewarding properties
or dependence (Slivicki et al, 2017).
Our preliminary data show that
GAT211 also enhances fear extinction
in auditory cue-induced fear condi-
tioning model and could potentially
provide a novel approach to PTSD
drug development.
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Integrating ‘Omics’
Approaches to Prioritize
New Pathogenetic
Mechanisms for Mental
Disorders
Neuropsychopharmacology research is
between a rock and a hard place. The
rock is the historical, but slow,
hypothesis-driven approach, where dis-
covery occurs by testing candidate me-
chanisms in already well-known
biological models. The hard place is the
innovative, but overwhelming,
hypothesis-free approach, where ‘omics’
analyses of everything that is analyzable
generates a deluge of data implicating
hitherto unknown mechanisms. So,
either we have little data on things we
already know, or too much data and
cannot find the needle in a haystack. One
solution is to mix apples and oranges:
integrating cross-species and cross-
tissues ‘omics’ data to find mechanisms
that recur across different experimental
and clinical models. The idea has been
used with remarkable success. And yes,
we will finish with the proverbs now.
Niculescu et al (2000) first developed
and used such an approach, which they
called convergent functional genomics.
More recently, the approach has been
used by them to help prioritize genes
from genome-wide association studies
(GWAS) of bipolar disorder (Patel
et al, 2010), integrating GWAS find-
ings, transcriptomics data on postmor-
tem human brain and blood, and
studies in animal models, to identify
top-genes supported by all approaches.
They identified six genes (ARNTL,
MBP, BDNF, NRG1, RORB, and
DISC1), which are involved in relevant
biological processes, such as circadian
rhythm, connectivity, and neuroplasti-
city. They used a similar strategy for
schizophrenia (Ayalew et al, 2012).
Interestingly, this strategy could be
done with publically available data
rather than being based on novel
experimental findings.
In 2013, we studied transcriptomics
data from the hippocampus of adult
prenatally stressed rats (an established
animal model of depression with high
glucocorticoid levels) and from a hu-
man neuronal stem cell line (that we
treated with a concentration of cortisol
that reduces neurogenesis) (Anacker
et al, 2013). We found that TGFβ-
SMAD2/3 and Hedgehog signaling
are reduced in both models: TGFβ-
SMAD2/3 promotes neurogenesis (and
has been found to be reduced in
depressed patients), whereas Hedgehog
promotes neuronal differentiation (and
has not been studied in depressed
patients yet). Similarly, Malki et al
(2016) studied transcriptomics from
the prefrontal cortex of mice bred for
high aggressive behavior and from the
brain of zebrafish exposed to aggres-
sive social encounters. They identified
seven genes shared in both datasets,
including HDAC4, which has genetic
variants associated with aggressive
behavior in mental retardation, and it
is targeted by valproic acid, a pharma-
cological treatment for aggressive be-
havior. Finally, Luoni et al (2016)
studied methylome analyses performed
in multiple models of early life stress:
rats exposed to prenatal stress (pre-
frontal cortex); human newborns ex-
posed to stress in pregnancy (cells
from the umbilical cord); and rhesus
monkeys exposed to stressful rearing
conditions (peripheral blood and pre-
frontal cortex). Their top gene was
Ank3, a gene with a strong association
for psychiatric disorders; and they also
demonstrated an interaction between
functional genetic variants within
Ank3 gene and obstetric complications
on working memory in humans.
Although these studies are predomi-
nantly ‘comparative’ in their nature,
this cross-species and cross-tissues
approach can be used to produce
‘integrative’ findings when it generates
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novel lists of overlapping or function-
ally related genes through statistical or
bioinformatic analysis.
With the collapse of R&D in mental
health by pharmaceutical companies,
convergent/integrative ‘omics’ ap-
proach represents a unique opportu-
nity for the scientific community to
mine existing datasets as well as data
from experimental and clinical models,
to prioritize targets for the psychotro-
pic medications of the future.
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A Translational Model to
Assess Sign-Tracking
and Goal-Tracking
Behavior in Children
Cues or stimuli in the environment can
guide behavior in adaptive ways, bring-
ing one in close proximity to valuable
resources (for example, food). For
some individuals, however, environ-
mental stimuli may acquire inordinate
control over behavior and elicit mala-
daptive tendencies or intrusive
thoughts. Thus, the way an individual
responds to cues in the environment
may be a key determinant of psycho-
pathology. For example, in addiction,
relapse is most often triggered by
exposure to stimuli (for example,
paraphernalia or places) previously
associated with the drug-taking experi-
ence, and people suffering from post-
traumatic stress disorder (PTSD) ex-
perience extreme anxiety or flashbacks
upon exposure to stimuli reminiscent
of a traumatic event. Furthermore, in
patients with schizophrenia, psychosis
is believed to result from aberrant
attribution of motivational salience to
environmental stimuli (Kapur, 2003).
Such stimuli are able to elicit complex
emotional and motivational states via
Pavlovian learning, and in recent years
we have come to rely on an animal
model to better understand these
processes (for review see Robinson
et al, 2014).
When exposed to a Pavlovian con-
ditioning paradigm wherein the pre-
sentation of a lever (conditioned
stimulus, CS) is followed by delivery
of a food reward (unconditioned
stimulus, US), some rats, termed
‘goal-trackers’ (GT), attribute predictive
value to the lever-cue and go to the
location of food delivery upon cue
presentation. Others, termed ‘sign-
trackers’ (ST), also attribute incentive
salience to the lever-cue, as evidenced
by their approach towards the cue and
the ability of the cue alone to act as a
reinforcer (for review see Robinson
et al, 2014). That is, for ST the reward
cue attains excessive incentive motiva-
tional value and gains inordinate con-
trol, leading to maladaptive behaviors.
Indeed, relative to GT, ST have also
been shown to be more impulsive, more
likely to exhibit cue-induced relapse to
drug-seeking behavior after relatively
little drug exposure, and more suscep-
tible to abnormal fear responses upon
exposure to aversive stimuli (for review
see Robinson et al, 2014). Thus, exam-
ining the translational relevance of the
sign-tracker/goal-tracker model may
prove critical to our understanding of
a number of cue-motivated psycho-
pathologies, including impulse control
disorders, addiction and post-traumatic
stress disorder.
To-date, little research has directly
examined sign- and goal-tracking be-
havior in humans (Garofalo and di
Pellegrino, 2015), and, to our knowl-
edge, none with children. Due to the
delayed development of the prefrontal
cortex (Casey et al, 2000), children
may be more likely to exhibit sign-
tracking behavior. Indeed, the lack of
cortical control and associated atten-
tional deficits and impulsive behavior
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